We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Merrimack Pharmaceuticals (MACK) is up more than 13% year to date (as of this writing). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Merrimack's business and drug pipeline.